BidaskClub upgraded shares of Xencor (NASDAQ:XNCR) from a hold rating to a buy rating in a research note released on Saturday morning, BidAskClub reports.

A number of other analysts have also commented on the stock. Mizuho reissued a buy rating on shares of Xencor in a research report on Wednesday, August 5th. Zacks Investment Research downgraded shares of Xencor from a hold rating to a sell rating in a report on Saturday, August 8th. SVB Leerink lowered their target price on shares of Xencor from $42.00 to $39.00 and set an outperform rating on the stock in a report on Tuesday, September 8th. Finally, Piper Sandler restated a buy rating and set a $46.00 target price on shares of Xencor in a report on Wednesday, July 8th. Three equities research analysts have rated the stock with a sell rating and eight have issued a buy rating to the stock. Xencor currently has a consensus rating of Hold and an average price target of $39.89.

Shares of XNCR stock opened at $40.77 on Friday. The company’s fifty day simple moving average is $33.90 and its 200-day simple moving average is $31.53. The firm has a market cap of $2.33 billion, a PE ratio of -29.12 and a beta of 0.94. Xencor has a 12 month low of $19.35 and a 12 month high of $42.08.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.61) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.05). The business had revenue of $13.09 million during the quarter, compared to the consensus estimate of $9.12 million. Xencor had a negative return on equity of 13.56% and a negative net margin of 113.40%. As a group, equities analysts predict that Xencor will post -1.7 EPS for the current year.

Several large investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC increased its holdings in shares of Xencor by 173.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,120 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 710 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of Xencor by 18.3% in the second quarter. Ameritas Investment Partners Inc. now owns 4,898 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 756 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Xencor by 24.0% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 4,728 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 915 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Xencor by 25.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,890 shares of the biopharmaceutical company’s stock valued at $146,000 after acquiring an additional 979 shares in the last quarter. Finally, TD Asset Management Inc. grew its stake in shares of Xencor by 1.3% in the second quarter. TD Asset Management Inc. now owns 90,584 shares of the biopharmaceutical company’s stock valued at $2,934,000 after acquiring an additional 1,200 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Featured Article: How do taxes affect a CDs total return?

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.